Haldol Tapering Guide
haloperidol
Boxed Warning
Increased mortality in elderly patients with dementia-related psychosis.
Overview
Haloperidol is a high-potency first-generation (typical) antipsychotic for schizophrenia, acute psychosis, and Tourette syndrome. Higher rates of EPS and tardive dyskinesia than atypicals; lower metabolic burden.
0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg tablets; 2mg/mL solution; 5mg/mL injection; 50mg, 100mg/mL decanoate depot
Tablets: 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg; Oral solution: 2mg/mL; IM lactate: 5mg/mL; IM decanoate (depot): 50mg/mL, 100mg/mL
Category C
Mechanism of Action
Potent D2 antagonist with little serotonin or histamine activity. The "clean" D2 blocker — drives both efficacy and EPS.
Taper Notes
Very slow taper recommended. Watch for tardive movement disorders unmasking. Switching to atypical may smooth the taper for some patients.
Hyperbolic Tapering Guidance
High-potency D2 antagonists carry a meaningful tardive risk that is often irreversible. Discuss this risk explicitly during informed consent.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
3-7 days (oral); weeks (depot)
2-4 weeks
4-8 weeks for acute symptoms
Tardive dyskinesia can emerge during or after taper and may be permanent
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- QT-prolonging drugs — additive risk
- CYP3A4/2D6 inhibitors — increase haloperidol levels
- Levodopa — antagonizes effect
Contraindications
- Severe CNS depression
- Parkinson disease
- Known hypersensitivity
Toxicity
EPS (acute dystonia, parkinsonism, akathisia), tardive dyskinesia, NMS, QT prolongation, hyperprolactinemia, sedation. Tardive risk is substantial with chronic high-dose use.
Pharmacokinetics
ADME Profile
Hepatic via CYP3A4, CYP2D6.
~92%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Haldol (haloperidol) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D 2021 — A method for tapering antipsychotic treatment that may minimize the risk of relapse (Schizophrenia Bulletin)
- Tranter R, Healy D 1998 — Antipsychotic withdrawal symptoms: phenomenology and pathophysiology (Journal of Psychopharmacology)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Royal College of Psychiatrists — Antipsychotics — UK clinical guidance on antipsychotic prescribing and discontinuation
- Council for Evidence-Based Psychiatry (CEP UK) — Evidence-based critique of long-term antipsychotic prescribing
- Deprescribing.org — Antipsychotic deprescribing algorithm for insomnia and BPSD
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — antipsychotic tapering forum — Community archive of antipsychotic taper experiences
- Mad in America — antipsychotic archive — Independent journalism on antipsychotics and withdrawal
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of antipsychotic adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.